AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Limb region 1 protein homolog

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8WVP7

UPID:

LMBR1_HUMAN

Alternative names:

Differentiation-related gene 14 protein

Alternative UPACC:

Q8WVP7; A4D242; Q8N3E3; Q96QZ5; Q9H5N0; Q9HAG9; Q9UDN5; Q9Y6U2

Background:

Limb region 1 protein homolog (LMBR1), also known as Differentiation-related gene 14 protein, plays a crucial role in limb development. This protein, encoded by the gene with accession number Q8WVP7, is implicated as a putative membrane receptor, indicating its potential involvement in signal transduction processes that are essential for the proper formation of limbs.

Therapeutic significance:

Mutations in LMBR1 are linked to a spectrum of limb malformations, including Preaxial polydactyly 2, Triphalangeal thumb with polysyndactyly, Acheiropody, Syndactyly 4, Hypoplasia or aplasia of tibia with polydactyly, and Laurin-Sandrow syndrome. These conditions highlight the protein's critical role in limb development pathways. Understanding the role of Limb region 1 protein homolog could open doors to potential therapeutic strategies for these congenital anomalies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.